HOLX Hologic Loading... : Bullish and Bearish Analyst Opinions
From ABT earnings callsLoading chart...
Top Calls
Feed
14:00
Jan 22
Jan 22
Abbott's continuous glucose monitoring (CGM) growth is slowing in percentage terms but maintaining a billion-dollar annual increase, with management citing SGLT2 crossover (only 1 million out of 6 million users on CGM) as a significant untapped market expansion opportunity. — This highlights a major growth segment for CGM that competitors like Dexcom (DXCM) and Medtronic (MDT) are also chasing, but Abbott's dominant market position and new dual-glucose ketone sensor could give it a decisive edge.
MED
About HOLX Analyst Coverage
Buzzberg tracks HOLX (Hologic) across 1 sources. 0 bullish vs 0 bearish calls from 1 analysts. Sentiment: evenly split. 1 total trade idea tracked. Latest voices: Robert Ford.